AACR 2023 4 20 贺菊颖SAC 编号：S1440517050001SFC 编号：ASZ591阳明春SAC编号：S1440521070004袁清慧SAC编号：S1440520030001SFC编号：BPW879研究助理：魏佳奥研究助理：王云鹏 2 AACR 4-6 ASCO EHA A 1ZCXxOrMmPpOsMtQmRsNpO7NdN9PmOpPsQpMjMqQrNkPsQnM6MmMzRwMnQuNuOrNnQ3 AACR 2023 04 AACR 3 HER2 ADC SHR-A1811 2 TROP2 ADC SHR-A1921 PD-1 IBI-351 KRAS G12C PD-1 BRAF IAP/ADC/Aurora A KRAS multi CD73 isac Tafasitamab ICP-490 ICP-189 EGFR/cMET TGF-/PD-L1 CD73 TEAD IDH1/2 HIF-2a APG-2575 APG-115 PD-1/TIGIT VEGF/TGF-/TLR8 KRAS G12C PD-L1 Ib PFS OS KN052 2 II EGFR/cMET ADC GQ1010 TROP2 ADC 4 A 资 料来源：Wind，中信 建投 公司代码 公司名称 投资评级总股本 收盘价 总市值 收入 PS(亿股)（元/股)（亿元）2022 2023E 2024E 2022 2023E 2024E1801.hk 15.35 38.35 541.62 45.6 59.2 79.1 11.9 9.1 6.8 1877.hk 9.86 29.95 271.60 14.5 27.1 35.8 18.7 10.0 7.6 9995.hk 5.44 46.40 232.33 7.7 13.9 22.7 30.2 16.7 10.2 6160.hk 13.58 147.40 1841.61 98.6 158.0 219.0 18.7 11.7 8.4 9926.hk 8.41 45.75 354.00 8.4 14.6 24.2 42.1 24.3 14.6 9688.hk 9.79 26.60 239.60 15.0 19.9 27.1 16.0 12.1 8.8 2162.hk 2.80 66.45 171.01 1.1 1.5 3.2 155.5 114.0 53.4 9969.hk 17.64 9.56 155.18 5.3 12.4 16.1 29.28 12.54 9.670013.hk 8.65 23.60 187.76 29.4 49.5 49.0 6.39 3.79 3.83公司代码 公司名称 投资评级总股本 收盘价 总市值 EPS PE(亿股)（元/股)（亿元）2022 2023E 2024E 2022 2023E 2024E600276.sh 63.97 46.01 2943.3 0.63 0.77 0.94 73.0 59.8 48.9002422.sz 14.71 29.43 432.9 1.17 1.50 1.66 25.2 19.6 17.7 5 4 ADC 1 HER2 ADC 2 6 3:7 8 12 10 13 ADC 9 14 Trop2 ADC,15 16 11 KN052 71 HER2 ADC AACR AACR 8 HER2 ADC TROP2 AACR 2023.04.14-04.19 SHR-A1811 HER2/LB031/23-SHR-A1811 HER2 ADC DAR HER2/CT175/7-SHR-A1811 HER2/1 HER2/CT204/17 SHR-A1811 HER2 NSCLC 1/2 SHR-A1921(Trop2)CT181/13-SHR-A1921 TROP-2-ADC FIH 1/LB030/22-SHR-A1921 TROP-2 ADC AACR AACR 9 HER2 ADC TROP2 SHR-A1811 HER2 ADC DAR T-Dxd SHR-A1811-Her2-SHR9265 DAR 7.5 ADC1 T-DXd-Her2-SHR9265 DAR 3.5 SK-BR-3 HER2 JIMT-1 HER2 capan-1 HER2 SHR-A1811 SHR-A1811 ADC1 SHR9265 SHR-A1811 21 2 SHR-A1811 40mpk 42 70mpk ADC1 10 I NCT0444620 1 8.0 mg/kg SHR-A1811 8mg/kg SHR-A1811 Cmax 3.85 ng/ml ILD 2 2.5%5.1%DAR SHR-A1811 SHR-A1811 II III NCT05424835 NCT05482568 NCT04818333 NCT05349409 AACR AACR 10 HER2 ADC TROP2 SHR-A1811 HER2/1 250 3 SHR-A1811 2022 9 28 1 DLT 243 97.2%TRAEs 131 52.4%3 TRAEs 31 12.4%TRAEs 3 1.2%8 3.2%AESI ORR 61.6%154/250 HER2 ORR 81.5%88/108 HER2 ORR 55.8%43/77 7/11 3/10/GEJ 5/9 5/8 1/3 1/2 1/1 ORR 1 6 PFS 73.9%AACR AACR 11 HER2 ADC TROP2 1.N=250 HER2 N=108 HER2 N=77 N=65 3 81.8%(45/55)58.7%(27/46)36.7%(18/49)3 81.1%(43/53)51.6%(16/31)31.3%(5/16)HER2 N=185*HER2 N=108 HER2 N=77 N=185 82.2%(88/107,73.7-89.0)68.8%(11/16,41.3-89.0)80.5%(99/123,72.4-87.1)81.9%(86/105,73.2-88.7)75.0%(9/12,42.8-94.5)81.2%(95/117,72.9-87.8)83.0%(39/47,69.2-92.4)100%(5/5,47.8-100)84.6%(44/52,71.9-93.1)86.9%(53/61,75.8-94.1)71.4%(5/7,29.0-96.3)85.3%(58/68,74.6-92.7)80.0%(28/35,63.1-91.6)100%(1/1,2.5-100)80.6%(29/36,64.0-91.8)T-DM1 82.4%(14/17,56.6-96.2)100%(3/3,29.2-100)85.0%(17/20,62.1-96.8)HER2-ADC T-DM1*60.0%(9/15,32.3-83.7)50.0%(2/4,6.8-93.2)57.9%(11/19,33.5-79.8)N=65 HER2 IHC3+IHC2+/ISH+N=36 HER2 IHC2+/ISH-IHC1+N=29 N=65%n/N 38.9%(14/36)31.0%(9/29)35.4%(23/65)n/N 95%CI n/N HER2 Clopper-Pearson 95%*RC48-ADC A166 DP303c MRG002 ARX788 TAA013 DX126-262 PF-06804103 BAT8001 AACR HER2 BC AACR 12 HER2 ADC TROP2 HER2 SHR-A1811 ORR 81.5%88/108 95%CI 72.9-88.3 DS-8201 DB03 ORR 79%250 3.2%DS-8201 DB03 DB04 12%-15%ORR3 TRAEs3 TEAEs SHR-A1811 HER2 I 3 1.0-8.0 mg/kg Q3W81.5%88/108 52.4%(-3.2%(/DS-8201 HER2 II 6 5 4 mg/kg Q3W62.00%(20.7%)(8.7%)(7.6%)13.60%/DS-8201 HER2 III T-DM1 3 69.70%10.40%/DS-8201 HER2 III 2 1-2 5 4 mg/kg Q3W79%-56%15%T-DM1 HER2 III 2 1-2 3 6 mg/kg Q3W35%-52%3%A166 HER2 I 4 4.8 and 6.0 mg/kg Q3W73.91%(17/23)68.57%(24/35)(34.5%)(22.4%)(10.3%)-*AACR HER2 BC AACR 13 HER2 ADC TROP2 HER2 SHR-A1811 ORR 55.8%43/77 95%CI 44.1-67.2 DS-8201 DB04 ORR 50%-60%MRG002 II ORR 34.7%ORR3 TRAEs3 TEAEs SHR-A1811HER2 I 3 1.0-8.0 mg/kg Q3W55.8%43/77,95%CI 44.1-67.2 52.4%(-3.2%(/DS-8201HER2 III 1-2 5 4 mg/kg Q3W CDK4/6 50.6%CDK4/6:58.3%Low disease burden:54%High disease burden 51.1%Rapid progression 50.0%no Rapid progression:52.4%-52.60%12.10%MRG002HER2 II 3 2.6 mg/kg Q3W34.70%neutrophil count decreased(14.3%)-*AACR AACR 14 HER2 ADC TROP2 SHR-A1811 HER2 NSCLC 1/2 2022 11 8 50 IV 3 1-8 HER2 TKI 66 68 78 96 HER2 8.0 mg/kg 1 4 4 4.8 mg/kg 38 5.6 95 CI 4.2-7.0 62 40.0 8.3 86.0 10.8(TRAEs)42%3 TRAEs(18%)SHR-A1811()AACR HER2/NSCLC AACR 15 ORR CR PR SD DCR mPFS3 TRAEs SHR-A1811HER2 NSCLCI 3 503.2,4.8,5.6,6.4,and 8.0 mg/kg Q3W40%-86%10.8m42%(30%)(20%)(16%)(12%)-/DS-8201HER2 NSCLC2-52+28 4.5 101+50 5.4mg/kg6.4 mg/kg Q3W53.8%42.9%1.9%3.6%51.9%39.3%36.5%50.0%90.4%92.9%-31.7%58.0%5.9%14.0%/DS-8201HER2 NSCLC-3 49+415.4mg/kg6.4 mg/kg Q3W34.1%26.5%4.9%0%29.3%26.5%43.9%42.9%78.0%69.4%8.2m22.0%53.1%4.9%20.4%HER2 ADC TROP2*AACR AACR 16 HER2 ADC TROP2 SHR-A1921 TROP-2 ADC Trop-2 ADC Trodelvy TINA-SHR79711 DS-1062 SKB264 SHR-A1921(1)TROP-2 TINA-SHR79711;(2)(3)TINA-SHR79711;(4)Trop-2 PSCC2 CDX FaDu Trop-2 CDX SK-OV-3 TGI 101 53 TINA-SHR79711 1 mpk 63 23 TINA-SHR79711 3 mpk 87 16 TINA-SHR79711 10 mpk;(5)SKB264 IMMU-132 2;(6)PK SKB264/ADC 1 vs.5-6;(7)T1/2 2.5 4.5 AACR AACR 17 HER2 ADC TROP2 SHR-A1921 TROP-2 ADC FIH 1 2022 10 21 38 18 1.5 mg/kg n=1 3.0 mg/kg n=4 4.0 mg/kg n=8 6.0 mg/kg n=5 20 3.0 mg/kg 71.1%27/38-PD-(L)1 NSCLC 4 3 6.0 mg/kg n=3 4.0 mg/kg n=1 4.0 mg/kg TRAEs 30%71.1%65.8%42.1%36.8%12 31.6%3 TRAEs n=7 18.4%2 TRAEs 10 NSCLC n=5 n=2 n=2 n=1 4 6 33.3%10/30 80.0%24/30 AACR TROP2 AACR 18 ORR DCR PR3 TRAEsTRAEs/TEAEs SHR-A1921I-156 38MTD 4.0 mg/kg 71.1%27/38 NSCLC 33.30%80%10 31.60%(TRAE)TRAE 30%71.1%65.8%42.1%36.8%/DS1062 Ib/140 38 13 25 37 20 17 4.0 mg/kg to 6.0 mg/kg/37%/41%84%/84%8/10 40%/60%(TEAE)TEAEs 56 29 41 48 28 38 25 36 16 36 ILD 1/2 3/DS1062 3 1-9 1804.0mg/kg 50 6.0mg/kg 50 8.0mg/kg 80 4.0 mg/kg to 8.0 mg/kg/24%/26%/24%-47%(TEAE)47%3 TEAEs 30%TEAEs 3 52%48%39%32%19 11%4 mg/kg 10%6 mg/kg 4%8 mg/kg 15%/3 2-7 5158.0mg/kg 8 10.0mg/kg 46 8.0 mg/kg to 10.0 mg/kg 19%-3 28%7%7%6%4%HER2 ADC TROP2 SHR-A1921 ORR 33.3%10 PR 3 TRAE 31.6%*19 2 20:AACR III/IBI-351 PD-1 III/III II MSS BCR-ABL IBI-351 KRAS G12C I 21:AACR 75%80%GIST KIT 5%10%PDGFRA TKIs BCL-2 80%GIST BCL-2 BCL-xL HQP1351 TKI BCR-ABL KIT PDGFRA GIST APG-2575 BCL-2 HQP1351 Bcl2 APG-2575 GIST GIST BCL-2 GIST HQP1351 Bcl2 GIST430 15 mg/kg 3 50 mg/kg 3 APG-2575 TGI 76.8%APG-2575 57.6%31.2%BCL-xL MCL-1 KIT STAT3 APG-2575 BCL-2:BIM TKI MCL-1 BCL-XL BCL-2 PARP-1 GIST APG-2575 TKIs GIST 22 IBI351 KRAS G12C-I IBI351 KRAS G12C KRAS G12C 2.9%-4.3%II NSCLC I 1 36 53.7%1 30 44.8%2 IBI351 AACR 23 IBI351 KRAS G12C-I TRAEs 94%=3 TRAE 31.3%600mg BID ORR 66.7%ORR 53.3%DCR 96.7%ORR 61.2%ORR 47.8%DCR 92.5%IBI351 AACR 24 IBI351 KRAS G12C-I TRAEs 94%=3 TRAE 31.3%600mg BID mPFS 8.2 9 PFS 47.3%IBI351 PFS AACR 25 Orient-15 III III AACR 26 mOS 17.4 12.8 HR 0.661 24 41.4%22.9%III AACR CPS=10 27 Orient-16 III III AACR 28 33.9 326 322 ORR 58.2%48.8%III AACR CPS=5 29 FGFR FGFR2 OS 31 16 51.6%1 8 25.8%2 7 22.6%3 II AACR 30 FGFR FGFR2 OS PFS 9.1 OS 23.6 II AACR 31 3:AACR AACR,32:AACR 2023.04.14-04.19 Tislelizumab PD-1 CT076/4-RATIONALE-306 tislelizumab 3/CT077/5-RATIONALE-302 TMB tislelizumab ESCC/LB289/2-RATIONALE-304 307 1L tislelizumab TIS+chemo NSCLC DNA ctDNA BGB-3245 BRAF a/b CT031-RAF BGB-3245 BGB-24714 IAP/6158/20-BGB-24714 IAP AACR AACR,33 649 370 57.0 2022 2 28 ITT Arm T+C n=182 15.8 Arm P+C n=188 10.6 Arm T+C vs Arm P+C 16.6 vs 11.2 HR 0.69 8.3 vs 5.6 HR 0.58 ORR 64.8 vs44.1 7.4 vs5.7 1 TRAE;98.8 vs 98.9 3 TRAE 72.9 vs 73.4 TRAE Arm T+C P+C 27.6 21.2 TRAE 2.9 1.6 Arm T+C P+C 28.2 17.4+OS PFS ORR DoR:AACR AACR,34TMB tislelizumab ESCC TIS ICC TMB TMB:TMB TMB-H TMB-L TIS ICC TIS ICCn(%in TMB BEP,N=209)27(12.9)31(14.8)78(37.3)73(34.9)ORR,%(95%CI)33.3(16.5,54.0)6.5(0.8,21.4)16.7(9.2,26.8)17.8(9.8,28.5)Median PFS,months(95%CI)2.4(1.4,5.5)2.3(1.3,2.9)1.4(1.3,2.7)2.7(1.5,3.3)PFS HR(95%CI)0.52(0.28,0.97)1.06(0.73,1.53)Interaction p-value 0.0537Median OS,months(95%CI)6.1(4.2,18.6)4.7(3.4,7.0)8.6(4.6,11.8)7.0(4.6,8.6)OS HR(95%CI)0.58(0.32,1.04)0.72(0.50,1.03)Interaction p-value 0.5374TMB-adjusted OS HR(95%CI)0.68(0.5,0.92)AACR AACR,35:+NSCLC DNA ctDNA ctDNA NSCLC TIS ctDNA(BL)(FR)RATIONALE-304 RATIONALE-307 RATIONALE-304 RATIONALE-307ctDNA UD D UD D UD D UD Dn 19 57 8 72 32 8 43 22mPFS,mo(95%CI)a9.23(5.75,9.89)9.69(7.33,14.52)NR(4.93,NR)9.76(7.52,14.55)17.31(9.89,NR)9.20(3.71,11.99)20.01(9.82,NR)9.56(7.39,13.9)PFS HR(95%CI),UD/D1.14(0.61,2.21)0.40(0.09,1.73)0.16(0.05,0.5)0.54(0.24,1.21)PFS P-valueb0.6421 0.2205 0.0019 0.1322mOS,mo(95%CI)NR(9.72,NR)NR(14,23,NR)NR(NR,NR)NR(16.89,NR)NR(NR,NR)18.78(9.92,NR)NR(NR,NR)NR(12.85,NR)OS HR(95%CI),UD/D1.04(0.48,2.25)NE 0.16(0.04,0.69)0.48(0.15,1.51)OS P-valueb0.9254 NE 0.0147 0.2079 AACR AACR,36BGB-3245 BRAF I 2022 9 1 42 6 5-60 mg QD 60 3 79 TRAE 29 TRAE 5 60%79%57%21%AE 10mg 40mg 60mg 40 mg QD MTD 79 48 CR 1 cPR 5 uPR 2 24 SD 8 2 BRAF V600E 1 CR 1 PR BRAF/MEK 1 NRAS G12S 1 NRAS Q61K 1 BRAF V600E LGSOC BRAF 1 BRAF V600E BRAF/MEK 1 BRAF K601E/PIK3CA 1 KRAS G12D DNA:AACR AACR,37BGB-24714 IAP BGB-24714 MDA-MB-231 cIAP1 EC50 2.5 nM BGB-24714 XIAP caspase-9 MDA-MB-231 caspase-9 EC50 23 nM TNF 25 BGB-24714 5 EC50 100 nM BGB-24714 MDA-MB-231 cIAP1 XIAP Smac BGB-24714 30 52 73 HCC1806 BGB-24714 BGB-24714 IAP BGB-24714:38 4 ADC AACR AACR 39 ADC AACR 2023.04.14-04.19 BL-B01D1 EGFRXHER3 ADC/2642/10-BL-B01D1 EGFR HER3-targeting ADC BL-M07D1 HER2 ADC/2643/11-BL-M07D1 HER2 ADC BL-M02D1 Trop2 ADC/2644/12-BL-M02D1 TROP2 ADC GNC-035 ROR1 ROR1+5679/28-GNC-035(GNC)ROR1+GNC-039 EGFR EGFRvIII+5680/29-GNC-039(GNC)EGFRvIII+GNC-038 CD19 CD19+5681/30-GNC-038(GNC)CD19+SI-B001 EGFRXHER3 EGFR 6309/16-SI-B001 EGFR HER3 EGFR AACR AACR 40 ADC BL-B01D1 EGFR HER3 ADC SW620 BxPC3 ADC BL-B01D1 EGFR ADC HER3 ADC BL-B01D1(NSCLC)I BL-M07D1 HER2 ADC BL-M07D1(CDX)1)HER2 CDX A431 NCI-H1975 BL-M07D1 DS-8201 2)HER2 JIMT-1 CDX BL-M07D1 3)BL-M07D1 NCI-N87 MDA-MB-468 HER2 HER2 BL-M07D1 T-DM1 DS-8201 AACR AACR 41 ADC BL-M02D1 TROP2 ADC trop2-Ed-04 ADC BL-M02D1 Trop2(hu4D3)B I(Ed-04)Ed-04 S BL-M02D1 DAR=8 IMMU-132 NCI-N87 MDA-MB-231 HCC827 BL-M02D1 IMMU-132 BL-M02D1 Trop2 Trop2(A431 SW620)BL-M02D1 IMMU-132 BL-M02D1 IMMU-132 42 5 AACR AACR 43 AACR 2023.04.14-04.19 JAB-2485 Aurora A/1645/2-JAB-2485 Aurora A JAB-23425(KRAS multi)/1660/17-KRASMulti JAB-23425 JAB-X1800(CD73 isac)/2923/1-JAB-X1800 CD73-iADC AACR AACR 44 JAB-2485 Aurora A JAB-2485 AURKA IC50 0.33nM AURKB 1700 JAB-2485 AURKA JAB-2485 SCLC TNBC G2/M SCLC SCLC TNBC JAB-2485 JAB-2485 1/2a(NCT05490472)JAB-2485 suppresses tumor growth in selected SCLC and neuroblastoma xenograft models AACR AACR 45 KRAS Multi JAB-23425 JAB-23425 KRAS G12D/G12V/G13D/G12A/G12R/Q61H KRAS KD JAB-23425 KRAS HRAS NRAS JAB-23425 KRAS Multi HRAS NRAS PK-PD JAB-23425 ERK JAB-23425 KRASG12D KRASG12V KRASG13D Antitumor activities of JAB-23425 as monotherapy in vivo AACR AACR 46 JAB-X1800 CD73 iADC-cd73 STING iADC JAB-X1800 JAB-X1800 pd-1 cd73 Synergy of JAB-X1800 in combination with anti-PD-1 JAB-X1800 exhibits potent anti-tumoractivity with immune memory and good tolerability in vivo 47 6 AACR 48 AACR 2023.04.14-04.19 B/4013/10-BTK orelabrutinib CD19 tafasitamab IMiD B tafasitamabDLBCL CT022-L-MIND tafasitamab DLBCL B/4013/10-BTK orelabrutinib CD19 tafasitamab IMiD B/6329/5-CD19 tafasitamab ICP-490/3427-ICP-490 IKZF1/3 ICP-189/4012/9-SHP2 ICP-189 AACR,AACR 49 AACR,CD19 tafasitamab TAFA mAb CD19 IHC CD19 TAFA IHC CD19 CD19 TAFA CD19 R/R DLBCL TAFA AACR 50 AACR,+tafasitamab+B CD19 tafasitamab r/r DLBCL tafasitamab tafasitamab ADCC B T NK tafasitamab r/r DLBCL AACR 51 AACR,ICP-490 IKZF1/3 ICP-490 MM NHL DLBCL ICP-490 NCI-H929 MM ICP-490 IL-2 B ICP-490 IKZF1/3 In Vivo Efficacy of ICP-490 in DLBCL Xenografts AACR 52 AACR,SHP2 ICP-189 ICP-189 MEK KRASG12C EGFR ICP-189 ICP-189 ICP-189 SHP2 SHP2 RAS/MAPK 53 7 AACR AACR 54 AACR 2023.04.14-04.19 BPI-452080 HIF-2a VHL 494/25-BPI-452080 HIF-2 von Hippel-Lindau BPI-221351 IDH1/2/495/26-BPI-221351 IDH1/2 BPI-460372 TEAD Hippo 501/1-BPI-460372 TEAD Hippo BPI-472372 CD73/504/4-BPI-472372 CD73 BPB-101 TGF-B/PDL1/6326/2-BPB-101 GARP-TGF/SLC TGF-PD-L1 EGFR/Met/4999/12-MCLA-129 EGFR c-MET amivantamab AACR AACR 55 BPI-452080 HIF-2 von Hippel-Lindau BPI-452080 HIF-2 VHL ccRCC BPI-452080 HIF-2 HIF-1 HIF-1 HIF1 VEGFA BPI-452080 BPI-452080 786-O PK/PD BPI-452080 ADME BPI-452080 HIF-2 ccRCC von Hippel-Lindau BPI-452080 2023 I AACR AACR 56 BPI-221351 IDH1/2 BPI-221351 IDH1 IDH2 BPI-221351 IDH1 IDH2 IDH1 IDH2 2-HG IDH BPI-221351 24 2-HG BPI-221351 BPI-221351 IDH1 IDH2 AACR AACR 57 BPI-460372 TEAD Hippo BPI-460372 TEAD BPI-460372 NF2 TEAD CTGF CYR61 mRNA BPI-460372 Hippo BPI-460372 NF2 LATS1/2 BPI-460372 ADME BPI-460372 TEAD Hippo2023 I AACR AACR 58 BPI-472372 CD73 BPI-472372 CD73 CD73 BPI-472372 AMP CD4+T BPI-472372 MC38 PD-L1 MC38 BPI-472372 PD-L1 BPI-472372 GLP 4 BPI-472372 BPI-472372 CD73 ADME BPB-101 GARP-TG F/SLC TGF-PD-L1 BPB-101 TME BPB-101 M7824 TGF-GARP TGF-MC38-hPD-L1 B6-hLRRC32 BPB-101 5mg/kg 93%p 0.001 PD-L1 nAb BPB-101 AACR AACR 59 MCLA-129 EGFR/c-MET amivantamab MCLA-129 MOA EGFR/c-MET amivantamab MOA MCLA-129 c-MET EGFR FACS MCLA-129 amivantamab EGFR c-MET 14 MCLA-129 c-MET HGF MCLA-129 amivantamab ADCC MCLA-129 ADCC amivantamab EGFR c-MET MCLA-129 Biclonics MOA c-MET EGFR ADCP ADCC amivantamab MCLA-129 1/2 MCLA-129 NSCLC 60 8 AACR AACR 61 AACR 2023.04.14-04.19 CPI CPI APG-2575 HQP1351 Bcl-2 APG-2575 lisaftoclax GISTs GIST GIST882 GIST-T1 GIST BCL-2.15mg/kg olverembatinib 3 50mg/kg lisaftoclax 3 olverembatinib lisaftoclax TGI 76.8%TGI olverembatinib lisaftoclax 57.6%31.2%APG-115 MDM2 alrizomadlin APG-115 MAPK UM MP41 alrizomadlin 25 50 100mg/kg TGI 24.8%38%39.1%alrizomadlin selumetinib APG-2449 TGI 65.4%47.5%AACR 1 BCR-ABL,HQP1351 Bcl-2 APG-2575 MDM2-p53 APG-115 62 9 AACR AACR 63 AACR 2023.04.14-04.19 ZG005 PD-1/TIGIT ZG005 PD-1 TIGIT IND,ZGGS18 VEGF/TGF-IND,ZG0895 TLR8 ZG0895 TLR8 T Treg ZG19018 KRAS G12C ZG19018 KRAS G12C-GDP GDP/GTP KRAS G12C NCI-H358 MIA PaCa-2 IND,biotech AACR PD-1/TIGIT ZG005 VEGF/TGF-ZGGS18 TLR8 ZG0895 KRAS G12C ZG19018 64 10 AACR 65 AACR 2023.04.14-04.19/TBQ2450 b CT200/13-TQB2450 Ib PFS OS AACR,PD-L1 AACR AACR AACR 66 TQB2450 NSCLC Ib PFS OS TQB2450 NSCLC TQB2450 TQB2450+10mg TQB2450+12mg TQB2450+mPFSn 33 34 34 68Censor,n(%)7(21.2)9(26.5)8(23.5)17(25.0)(95%CI)2.8(1.4-4.7)7.0(4.5-14.5)8.7(4.1-11.4)7.3(5.3-11.0)HR(95%CI)0.37(0.21-0.66)0.40(0.22-0.70)0.39(0.23-0.64)P value 0.0006 0.0001mPFS(PD-L11%)n 19 19 19 38Censor,n(%)3(15.8)6(31.6)7(36.8)13(34.2)(95%CI)2.1(1.3-7.2)7.0(2.1-19.4)17.9(5.8-31.1)8.6(5.3-22.8)HR(95%CI)0.35(0.16-0.77)0.29(0.13-0.64)0.32(0.16-0.63)P value 0.0023 0.0006mOSn 33 34 34 68Censor,n(%)12(36.4)14(41.2)12(35.3)26(38.2)(95%CI)15.3(6.6-20.5)20.6(8.6-25.8)14.7(10.0-32.2)17.9(10.5-23.2)HR(95%CI)0.78(0.42-1.44)0.84(0.46-1.53)0.81(0.48-1.37)P value 0.7157 0.4329mOS(PD-L11%)n 19 19 19 38Censor,n(%)5(26.3)7(36.8)8(42.1)15(39.5)(95%CI)15.7(7.8-21.0)21.8(7.1-NR)32.2(14.2-33.6)21.8(14.2-33.6)HR(95%CI)0.72(0.33-1.58)0.63(0.28-1.40)0.67(0.34-1.32)P value 0.49 0.2479 67 11 KN052 AACR 68 KN052 AACR 2023.04.14-04.19 KN052 PD-L1/OX40/LB021/13-KN-052 PDL1/OX40 AACR,KN052 AACR AACR 69 KN052 KN052 PD-